Over the past twenty years, the number of new skin cancer cases in Belgium has surged by 500 percent, making melanoma the country’s fastest-growing oncological threat with more than 4,285 new diagnoses recorded annually.
That reality changes European public health. While new diagnoses climb, medical outcomes are steadily improving thanks to early detection and advanced therapies, according to data released by the Belgian Cancer Registry and reported by Lalibre.be. Ces dernières années, on a progressé remarquablement,
a specialist noted.
Dermatologues found that the median thickness, known as Breslow thickness, of lesions decreased, a trend observed principally in Flanders where it dropped from 1.0 mm in 2009 to 0.7 mm in 2024. Dermatologists face a dual battle on the ground. Beyond treating rising patient volumes, medical professionals must contend with viral misinformation on social media platforms that disparage sun protection creams or frame tanning as a sign of health, Lalibre.be reported.
Long waiting lists for specialist consultations add another layer of friction to preventative care efforts. Reducing excessive ultraviolet exposure and strengthening early screening remain central pillars of the nation’s new Cancer Plan for 2026 through 2036, according to the same reporting.
Despite the climbing incidence rates, clinical outcomes tell an encouraging story. Net five-year survival rates for melanoma patients diagnosed between 2020 and 2024 reached 96 percent, up from 88 percent between 2004 and 2009, Lalibre.be noted.
Advances in medical research continue to shift prognoses for patients with advanced disease. For stage III diagnoses involving lymph node involvement, net five-year survival climbed to 73 percent for diagnostics logged between 2020 and 2024, compared to 59 percent for those recorded between 2004 and 2009, according to data cited by Lalibre.be.
Even at stage IV, where distant metastases are present, net five-year survival rose from 27 percent to 39 percent over the same timeline. Professor Bart Neyns, head of medical oncology at UZ Brussel, attributed these gains directly to innovations such as immunotherapy, which achieves durable disease control in advanced cases, Lalibre.be reported.
| Melanoma Stage | 2004–2009 Survival Rate | 2020–2024 Survival Rate |
|---|---|---|
| All Stages Combined (Net 5-Year) | 88% | 96% |
| Stage III (Lymph Node Involvement) | 59% | 73% |
| Stage IV (Metastatic) | 27% | 39% |
Professor Pierre Coulie, co-president of the Cancer Foundation, emphasized that sustained funding for scientific research remains vital for improving both survival statistics and patient quality of life, Lalibre.be stated. Policymakers and oncologists continue to stress that stopping the disease before it develops is just as critical as engineering new treatments.
